Chemoinformaics analysis of (Z)6,(Z)9-Pentadecadien-1-ol
| Molecular Weight | 224.388 | nRot | 11 |
| Heavy Atom Molecular Weight | 196.164 | nRig | 2 |
| Exact Molecular Weight | 224.214 | nRing | 0 |
| Solubility: LogS | -4.895 | nHRing | 0 |
| Solubility: LogP | 5.41 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 16 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 28 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 44.5222 |
| nHD | 1 | BPOL | 28.0898 |
| QED | 0.401 |
| Synth | 2.373 |
| Natural Product Likeliness | 1.52 |
| NR-PPAR-gamma | 0.386 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.312 |
| HIA | 0.006 |
| CACO-2 | -4.41 |
| MDCK | 0.0000202 |
| BBB | 0.464 |
| PPB | 0.963788 |
| VDSS | 2.513 |
| FU | 0.0295944 |
| CYP1A2-inh | 0.935 |
| CYP1A2-sub | 0.183 |
| CYP2c19-inh | 0.407 |
| CYP2c19-sub | 0.058 |
| CYP2c9-inh | 0.45 |
| CYP2c9-sub | 0.916 |
| CYP2d6-inh | 0.024 |
| CYP2d6-sub | 0.141 |
| CYP3a4-inh | 0.414 |
| CYP3a4-sub | 0.058 |
| CL | 9.951 |
| T12 | 0.408 |
| hERG | 0.03 |
| Ames | 0.02 |
| ROA | 0.009 |
| SkinSen | 0.966 |
| Carcinogencity | 0.211 |
| EI | 0.976 |
| Respiratory | 0.251 |
| NR-Aromatase | 0.413 |
| Antiviral | Yes |
| Prediction | 0.786791 |